Lyra Health vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 58)
Lyra Health logo

Lyra Health

ChallengerHealthcare Tech

Mental Health Benefits & Digital Therapeutics

Leading mental health benefits platform for employers. Founded 2015 by ex-Facebook CFO. $5.58B valuation, $915M total funding. Serves 20M+ people through employer contracts.

AI VisibilityBeta
Overall Score
C58
Category Rank
#144 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
52
Perplexity
53
Gemini
56

About

Lyra Health is a workforce mental health platform founded in 2015 by David Ebersman (former CFO of Facebook/Meta) and Dena Bravata, headquartered in Burlingame, California. It provides AI-powered mental health benefits to employers through therapy, coaching, preventive care, specialized programs (substance use, DBT), and the Empower AI platform for personalized support.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

58
Overall Score
81
#144
Category Rank
#17
71
AI Consensus
71
stable
Trend
stable
52
ChatGPT
80
53
Perplexity
75
56
Gemini
77
57
Claude
86
64
Grok
85

Key Details

Category
Mental Health Benefits & Digital Therapeutics
General
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Lyra Health
Mental Health Benefits & Digital Therapeutics

Integrations

Only Lyra Health
Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.